- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06045429
Oral Care With 3% Hydrogen Peroxide (Oroxid®) in ICU - Effects on the Lower Airway Microbial Colonisation (HyperMICROBE)
Effects of Oral Care With 3% Hydrogen Peroxide (Oroxid®) on the Lower Respiratory Tract Microbial Colonisation in Mechanically Ventilated Adult Critically Ill Patients (HyPer-MICROBE Trial); a Single-centre, Randomised, Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale: Ventilator-associated pneumonia (VAP) is the most common hospital-acquired infection (HAI) in the intensive care unit (ICU), and its impact is very high in terms of morbidity, length of hospital stay and overall costs. Chlorhexidine for oral care in critically ill has no clear impact on VAP rates and may cause harm. 3% hydrogen peroxide (Oroxid) could be a promising substitute.
Aim: To test effectivity and safety of 3% hydrogen peroxide solution on ventilator-associated complications
Design: Prospective, single center, parallel group randomised controlled trial. Subjects: ICU patients (general ICU)
Treatment in the intervention group: daily oral care with 3% hydrogen peroxide
Control group: Standard-of-care protocolised daily oral care with 0,2% chlorhexidine
Primary outcome: Cumulative incidence of lower respiratory tract microbial colonisation analysed by Kaplan-Maier method, censored in the case of ICU discharge or extubation > 24h.
Secondary and exploratory outcomes: Differences in the relative risk of infection related ventilator-associated complications, antibiotic (ATB) consumption analysis, intraoral complications, reported using the Bedside oral exam (BOE) score, validated and adopted for ICU, length of ICU stay in days (time frame: at 3 months), number of ventilator-free days (time frame: at 28 days); that is, number of days, out of 28 days after admission, that patient has not been supported by mechanical ventilation
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years
- In-patient of ICU and expected to stay > 5 days
- Mechanical ventilation or imminent need of it; predicted length of mechanical ventilation (MV) ≥ 72h
- Clinical Pulmonary Infection score (CPIS) less than 6 at the baseline
- No history and symptoms of aspiration at the baseline
Exclusion Criteria:
- ATB therapy on admission
- Suspected pulmonary infection on admission and in the first 48h of mechanical ventilation
- Pregnancy
- Oral ulcers or injuries
- Patient with a history of hydrogen peroxide allergy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hydrogen Peroxide
Intervention group: daily oral care will be provided according to the local standard, with 3% hydrogen peroxide, oral assessment and teeth brushing will be completed twice daily (morning and evening).
|
All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local "ventilator bundle "; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation.
This reflects current practice.
Daily oral care will be provided using Oroxid® mouthwash.
Other Names:
|
Active Comparator: Chlorhexidine
Control group: daily oral care will be provided according to the local standard, with 0,2% chlorhexidine, oral assessment and teeth brushing will be completed twice daily (morning and evening).
|
All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local "ventilator bundle "; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation.
This reflects current practice.
Daily oral care will be provided using 0,2% chlorhexidine
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative incidence of lower respiratory tract microbial colonisation analysed by Kaplan-Maier method, censored in the case of ICU discharge or extubation > 24h.
Time Frame: 18 months
|
To detect microorganisms in the lower respiratory tract, tracheal aspirate will be directly cultured for detecting Gram-positive, Gram-negative, and anaerobic bacteria and fungi.
Standard microbial surveillance (tracheal aspirate) will be performed on admission, twice a week (Monday, Thursday) and always ad hoc according to the clinical situation.
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Differences in the relative risk of infection related ventilator associated complications (IVAC)
Time Frame: 18 months
|
According to the Centers for Disease Control and Prevention (CDC) criteria, the IVAC diagnosis will be established based on:
|
18 months
|
ATB exposure at discharge
Time Frame: From the date of enrolment through to the date of ICU discharge, approximately 28 days
|
Duration of antibiotics prescribed at discharge
|
From the date of enrolment through to the date of ICU discharge, approximately 28 days
|
Intraoral complications, reported using the Bedside oral exam (BOE) score, validated and adopted for ICU.
Time Frame: will be measured at 24 hours (T1), day 3 (T2), day 7 (T3) and day 14 (T4) after admission
|
BOE score ranges from 8 (excellent oral health) to 24 (poor oral health).
The BOE scores ranging from 8-10 are considered as indicative of excellent oral health, from 11-14 as moderately impaired oral health and from 15-24 as significantly impaired oral health
|
will be measured at 24 hours (T1), day 3 (T2), day 7 (T3) and day 14 (T4) after admission
|
Length of ICU stay in days
Time Frame: at 3 months
|
that is, length of ICU stay in days
|
at 3 months
|
Number of ventilator-free days;
Time Frame: at 28 days
|
that is, number of days, out of 28 days after admission, that patient has not been supported by mechanical ventilation
|
at 28 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composition of the oral and lower airway microbiome between groups measured by the bacterial 16S rRNA sequencing
Time Frame: day 0, day 7 and day 14
|
Microbial DNA will be sequentially (on admission, day 3, 7 and 14) sampled and isolated from prespecified sites in oral cavity, hypopharynx and lower respiratory tract.
Microbial DNA will be analyzed by 16S rRNA amplicon sequencing and quantified by multiplex qPCR method.
Paired comparison of bacteriomes between intervention group and control group will be performed to identify potentially risky host bacteriome profiles.
|
day 0, day 7 and day 14
|
Antibiotic Free Days
Time Frame: up to 30 days
|
The number of days where participant did not require the use of antibiotics
|
up to 30 days
|
The number of participants with Non-pulmonary infections
Time Frame: up to 30 days
|
The number of participants with Non-pulmonary infections
|
up to 30 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Disease Attributes
- Cross Infection
- Iatrogenic Disease
- Healthcare-Associated Pneumonia
- Infections
- Communicable Diseases
- Pneumonia
- Pneumonia, Ventilator-Associated
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Dermatologic Agents
- Disinfectants
- Chlorhexidine
- Hydrogen Peroxide
- Chlorhexidine gluconate
Other Study ID Numbers
- VP/46/0/2022
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on VAP - Ventilator Associated Pneumonia
-
Ain Shams UniversityCompletedSepsis | Ventilator Associated Pneumonia ( VAP)Egypt
-
University of MichiganNational Institutes of Health (NIH); National Center for Advancing Translational...CompletedVAP - Ventilator Associated PneumoniaUnited States
-
Cubist Pharmaceuticals LLCTerminatedVentilator-Associated Pneumonia (VAP)United States, Australia, New Zealand
-
Assiut UniversityNot yet recruitingVAP - Ventilator Associated Pneumonia
-
Ain Shams UniversityCompletedVAP - Ventilator Associated PneumoniaEgypt
-
Muğla Sıtkı Koçman UniversitySuspendedVentilator-associated Pneumonia (VAP)Turkey
-
Erasmus Medical CenterChiesi Farmaceutici S.p.A.CompletedVentilator Associated Pneumonia (VAP)Spain, Netherlands
-
Andrzej Frycz Modrzewski Krakow UniversityCompletedVAP - Ventilator Associated PneumoniaPoland
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
BioMérieuxNot yet recruiting
Clinical Trials on Oroxid®
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Chong Kun Dang PharmaceuticalCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Diphtheria | PolioUnited States
-
Chung-Ang University Hosptial, Chung-Ang University...UnknownFunctional DyspepsiaKorea, Republic of
-
Amir AzarpazhoohInstitut Straumann AGCompletedPeriodontal Inflammation | Crown LengtheningCanada
-
Novartis PharmaceuticalsCompletedPulmonary Disease, Chronic Obstructive (COPD)Argentina
-
GuerbetCompletedPrimary Brain TumorColombia, Korea, Republic of, United States, Mexico
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussisUnited States